# Eloxx Pharmaceuticals, Inc.: filings

ELOX · Nasdaq · CIK 1035354 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elox.md) · [Financials](/companies/elox/financials.md) · [Filings](/companies/elox/filings.md) · [Insiders](/companies/elox/insiders.md)

## Reports and events: 374 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 388, 8-K 246, 10-Q 47, 3 41, SC 13G 19, 424B5 17, SC 13G/A 17, 10-K 16, DEF 14A 16, S-8 13, SC 13D/A 13, SCHEDULE 13G 10, 10-K/A 9, 4/A 9, CORRESP 9, DEFA14A 9, EFFECT 9, CT ORDER 8, S-1/A 8, 8-K/A 7, PRE 14A 7, SC 13D 7, ARS 6, NT 10-Q 6, S-3 6, 424B3 5, NT 10-K 5, S-1 5, UPLOAD 5, 424B4 3, 25-NSE 2, 8-A12B 2, CERT 2, D 2, DEF 14C 2, SCHEDULE 13G/A 2, DRS 1, FWP 1, NT 10-K/A 1, NT 10-Q/A 1, PRE 14C 1, RW 1, S-1MEF 1, S-3/A 1, SC 14F1 1, SEC STAFF ACTION 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 23:31 ET | [8-K](/filings/0001193125-26-428116.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001193125-26-428116 |
| 2026-09-11 | 21:28 ET | [S-1](/filings/0001193125-26-389422.md) | Registration statement | 0001193125-26-389422 |
| 2026-08-11 | 21:19 ET | [8-K](/filings/0001193125-26-345032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345032 |
| 2026-08-11 | 21:02 ET | [10-Q](/filings/0001193125-26-344964.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344964 |
| 2026-06-04 | 21:17 ET | [S-1/A](/filings/0001193125-26-257750.md) | Registration statement, amended | 0001193125-26-257750 |
| 2026-06-01 | 20:55 ET | [S-1/A](/filings/0001193125-26-251655.md) | Registration statement, amended | 0001193125-26-251655 |
| 2026-06-01 | 11:00 ET | [8-K](/filings/0001193125-26-249692.md) | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-249692 |
| 2026-05-07 | 20:57 ET | [S-1](/filings/0001193125-26-212324.md) | Registration statement | 0001193125-26-212324 |
| 2026-05-05 | 01:04 ET | [10-Q](/filings/0001193125-26-204722.md) | Quarterly report, period 2026-03-31 | 0001193125-26-204722 |
| 2026-05-01 | 20:05 ET | [8-K](/filings/0001193125-26-201408.md) | 5.07 Shareholder vote results | 0001193125-26-201408 |
| 2026-03-17 | 21:44 ET | [10-K](/filings/0001193125-26-108687.md) | Annual report, period 2025-12-31 | 0001193125-26-108687 |
| 2025-08-12 | 21:22 ET | [8-K](/filings/0001104659-25-076933.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-25-076933 |
| 2024-10-17 | 20:01 ET | [8-K](/filings/0001104659-24-109521.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-24-109521 |
| 2024-08-20 | 00:13 ET | [SC 13D/A](/filings/0001062993-24-015470.md) | Ownership report, active investor, amended | 0001062993-24-015470 |
| 2024-07-16 | 21:23 ET | [8-K](/filings/0001104659-24-080251.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-24-080251 |
| 2024-03-29 | 20:11 ET | [8-K](/filings/0001104659-24-041148.md) | 5.02 Departure or appointment of officers or directors | 0001104659-24-041148 |
| 2024-03-14 | 20:30 ET | [8-K](/filings/0001104659-24-034529.md) | 1.01 Entry into a material agreement | 0001104659-24-034529 |
| 2024-01-09 | 22:10 ET | [8-K](/filings/0001104659-24-002631.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001104659-24-002631 |
| 2023-12-28 | 21:11 ET | [8-K](/filings/0001104659-23-130052.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-23-130052 |
| 2023-12-15 | 21:10 ET | [8-K](/filings/0001104659-23-126400.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-23-126400 |
| 2023-11-13 | 21:58 ET | [8-K](/filings/0001104659-23-117308.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-117308 |
| 2023-11-13 | 21:10 ET | [10-Q](/filings/0000950170-23-062940.md) | Quarterly report, period 2023-09-30 | 0000950170-23-062940 |
| 2023-10-16 | 21:26 ET | [8-K](/filings/0001104659-23-109423.md) | 3.01 Delisting notice | 0001104659-23-109423 |
| 2023-09-20 | 20:05 ET | [8-K](/filings/0001104659-23-102293.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-23-102293 |
| 2023-09-18 | 12:05 ET | [8-K](/filings/0001104659-23-101394.md) | 8.01 Other events | 0001104659-23-101394 |
| 2023-09-15 | 21:15 ET | [8-K](/filings/0001104659-23-101272.md) | 5.02 Departure or appointment of officers or directors | 0001104659-23-101272 |
| 2023-09-07 | 14:14 ET | [8-K](/filings/0001104659-23-098843.md) | 8.01 Other events | 0001104659-23-098843 |
| 2023-08-29 | 20:32 ET | [8-K](/filings/0001104659-23-096572.md) | 5.02 Departure or appointment of officers or directors | 0001104659-23-096572 |
| 2023-08-21 | 20:50 ET | [8-K](/filings/0001104659-23-093964.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-23-093964 |
| 2023-08-14 | 15:56 ET | [8-K](/filings/0001104659-23-091130.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001104659-23-091130 |
| 2023-08-11 | 20:05 ET | [10-Q](/filings/0000950170-23-041837.md) | Quarterly report, period 2023-06-30 | 0000950170-23-041837 |
| 2023-08-03 | 20:01 ET | [8-K](/filings/0001104659-23-087248.md) | 8.01 Other events | 0001104659-23-087248 |
| 2023-07-13 | 12:43 ET | [8-K](/filings/0001104659-23-080576.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-080576 |
| 2023-06-23 | 22:32 ET | [8-K](/filings/0001104659-23-073875.md) | 5.07 Shareholder vote results | 0001104659-23-073875 |
| 2023-06-15 | 13:15 ET | [8-K](/filings/0001104659-23-071430.md) | 8.01 Other events | 0001104659-23-071430 |
| 2023-06-07 | 00:32 ET | [8-K](/filings/0001104659-23-068637.md) | 8.01 Other events | 0001104659-23-068637 |
| 2023-05-24 | 12:07 ET | [8-K](/filings/0001104659-23-063884.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-063884 |
| 2023-05-16 | 22:01 ET | [8-K](/filings/0001104659-23-060978.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-060978 |
| 2023-05-12 | 20:41 ET | [10-Q](/filings/0000950170-23-021821.md) | Quarterly report, period 2023-03-31 | 0000950170-23-021821 |
| 2023-04-28 | 20:03 ET | [DEF 14A](/filings/0001140361-23-021490.md) | Proxy statement, period 2023-06-22 | 0001140361-23-021490 |
| 2023-04-14 | 20:06 ET | [8-K](/filings/0001104659-23-045573.md) | 3.01 Delisting notice | 0001104659-23-045573 |
| 2023-04-03 | 13:27 ET | [8-K](/filings/0001104659-23-040585.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-040585 |
| 2023-03-31 | 20:02 ET | [10-K](/filings/0000950170-23-011360.md) | Annual report, period 2022-12-31 | 0000950170-23-011360 |
| 2023-03-09 | 21:12 ET | [8-K](/filings/0000950170-23-007032.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0000950170-23-007032 |
| 2022-12-01 | 22:04 ET | [8-K](/filings/0001104659-22-123704.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-123704 |
| 2022-11-14 | 21:09 ET | [8-K](/filings/0001104659-22-118535.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-118535 |
| 2022-11-10 | 21:18 ET | [10-Q](/filings/0000950170-22-024490.md) | Quarterly report, period 2022-09-30 | 0000950170-22-024490 |
| 2022-10-31 | 20:31 ET | [DEF 14A](/filings/0001140361-22-039123.md) | Proxy statement, period 2022-11-30 | 0001140361-22-039123 |
| 2022-10-14 | 20:31 ET | [8-K](/filings/0001104659-22-108877.md) | 3.01 Delisting notice | 0001104659-22-108877 |
| 2022-09-15 | 12:07 ET | [8-K](/filings/0001104659-22-100245.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-100245 |

Page 1 of 8. [Older](/companies/elox/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:04 ET. No prices; not investment advice.